摘要
目的 探讨安罗替尼治疗晚期卵巢癌的疗效。方法 将60例晚期卵巢癌患者按治疗方式的不同分为紫杉醇+卡铂(TP)组(n=28)和安罗替尼组(n=32)。TP组患者采取TP方案化疗,安罗替尼组患者在TP组的基础上联合安罗替尼治疗。比较两组患者的疗效、肿瘤标志物水平、凋亡因子水平、血管生成因子水平。结果 安罗替尼组患者总缓解率高于TP组患者,差异有统计学意义(P﹤0.05)。治疗后,两组患者β-人绒毛膜促性腺激素(β-HCG)、糖类抗原125(CA125)、人附睾蛋白4(HE4)、存活蛋白(survivin)、B细胞淋巴瘤/白血病-2(Bcl-2)、Bcl-2相关凋亡基因1(BAG1)、基质金属蛋白酶2(MMP2)、血管内皮生长因子(VEGF)、缺氧诱导因子-1α(HIF-1α)、血管生成素2(ANGPT2)水平均降低,且安罗替尼组患者β-HCG、CA125、HE4、BAG1、survivin、Bcl-2、MMP2、VEGF、HIF-1α、ANGPT2水平均低于TP组,差异均有统计学意义(P﹤0.05)。结论 安罗替尼治疗晚期卵巢癌患者疗效显著,其作用机制可能与血管生成因子及凋亡因子有关。
Objective To investigate the efficacy of anlotinib in the treatment of advanced ovarian cancer.Method A total of 60 patients with advanced ovarian cancer were divided into paclitaxel plus carboplatin(TP)group(n=28)and anlotinib group(n=32)according to different treatment regimens.The patients in the TP group were treated with TP regimen chemotherapy,and the patients in the anlotinib group were treated with anlotinib based on the TP regimen.The curative effect,tumor marker levels,apoptosis factor levels,and angiogenesis factor levels were compared between the two groups.Result The overall response rate of patients in the anlotinib group was higher than that in the TP group,and the difference was statistically significant(P<0.05).After the treatment,the levels ofβ-human chorionic gonadotrophin(β-HCG),carbohydrate antigen 125(CA125),human epididymis protein 4(HE4),survivin,B-cell lymphoma/leukemia-2(Bcl-2),Bcl-2 associated athanogene(BAG1),matrix metalloproteinase 2(MMP2),vascular endothelial growth factor(VEGF),hypoxia-inducible factor-1α(HIF-1α),angiopoietin 2(ANGPT2)in the two groups were all decreased,and the levels of the above indicators in the anlotinib group were lower than those in the TP group,and the differences were statistically significant(P<0.05).Conclusion Anlotinib has a remarkable effect in treating patients with advanced ovarian cancer,and its underlying mechanism is related to angiogenesis factors and apoptosis factors.
作者
李成彪
顾刚寿
LI Chengbiao;GU Gangshou(Department of Medical Oncology,Wuwei People’sHospital,Wuwei 733000,Gansu,China)
出处
《癌症进展》
2023年第13期1420-1423,共4页
Oncology Progress
基金
甘肃省科技计划项目(20JR10RA779)。
关键词
卵巢癌
临床疗效
安罗替尼
凋亡因子
ovarian cancer
clinical efficacy
anlotinib
apoptosis factor
